Citations

Showing 10 of 108094 citations.

Combined ibrutinib and venetoclax for treatment of patients with ibrutinib‐resistant or double‐refractory chronic lymphocytic leukaemia
Hampel, Paul J. , Rabe, Kari G. , Call, Timothy G. , Leis, José F., Kenderian, Saad S. , Muchtar, Eli , Wang, Yucai , Koehler, Amber B. , Parrondo, Ricardo , Schwager, Susan M., Braggio, Esteban , Kenderian, Saad Sirop , Muchtar, E , Wang, Yucai , Parrondo, Ricardo D , Shi, Min , Parikh, Sameer A , Chaffee, Kari G. , Braggio, Esteban , Ding, Wei , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

British Journal of Haematology | July 16, 2022 | Volume: 199 | Issue: 2 | Pages: 239-244

10.1111/bjh.18357 | PMID 35841338 Get It

SummaryPatients with chronic lymphocytic leukaemia (CLL) disease progression on ibrutinib or after sequential ibrutinib and venetoclax‐based treatments (double‐refractory) have poor outcomes. In this retrospective study, we analysed outcomes with combined ibrutinib and venetoclax treatment in these groups of patients. The median treatment‐free and overall survival for 22 patients with prior progression on ibrutinib (venetoclax‐naïve) were 23.7 and 47.1 months respectively. In 11 patients with double‐refractory CLL, the median treatment‐free and overall survival were 11.2 and 27.0 months respectively. The combination of ibrutinib and venetoclax may help bridge the current gap in options for patients with disease refractory to the most commonly used novel agents.
Characteristics and outcomes of left ventricular assist device recipients transplanted before and after the new donor heart allocation system
Doulamis, Ilias P. , Mandarada, Tejaswini, Asleh, Rabea , Asleh, Rabea , Briasoulis, Alexandros , Inampudi, Chakradhari , Kourek, Christos , Kuno, Toshiki , Briasoulis, Αlexandros

Mayo Clinic

Artificial Organs | July 16, 2022 | Volume: 46 | Issue: 12 | Pages: 2460-2468

10.1111/aor.14363 | PMID 35841284 Get It

AbstractBackgroundConcerns about the impact of the new donor heart allocation system on posttransplant outcomes have emerged after its implementation. We sought to evaluate the characteristics and outcomes of left ventricular assist device (LVAD) recipients transplanted before and after the implantation of the new policy on October 18, 2018.MethodsData on bridge to transplantation of adult patients with LVAD between January 2015 and October 2021, with durable LVAD as a (BTT), was queried from the United Network of Organ Sharing (UNOS) registry. The main outcomes were 30‐day all‐cause mortality, 30‐day fatal graft failure, 1‐year all‐cause mortality, treated acute rejection at 1 year and renal replacement therapy (RRT) for acute renal failure.ResultsIn our study, 7096 patients met the inclusion criteria including 2435 in the new allocation system. The transplanted patients in the new allocation system era had older donor age, longer ischemic time, and higher proportion of newer generation LVADs. Adjusted 30‐day all‐cause mortality was significantly lower for LVAD recipients in the new allocation system era (2.5% vs. 3.6%; sub‐hazard ratio [SHR] 0.36, 95% Confidence intervals [CI] 0.27–0.48, p < 0.001) without differences in the risk of fatal graft failure and 1‐year mortality (7.8% vs. 9.6%). Significantly lower adjusted 30‐day mortality with HVAD and HM3 devices than HM2 in the new allocation system era was found, without differences in 1‐year mortality. Acute allograft rejection requiring treatment was significantly lower (Odds Ratio 0.78, 95% CI 0.65–0.94, p = 0.01), whereas a trend toward higher risk of renal failure requiring RRT was identified.ConclusionsDespite changing donor characteristics and longer ischemic times, posttransplant outcomes in LVAD recipients have not worsened with the implementation of the new allocation system and this finding is related to the use of newer generation continuous flow LVADs.
Complications and re‐operations after extensor mechanism repair surgery in a large cross‐sectional cohort: females and tobacco‐users at highest risk for adverse outcomes
Oeding, Jacob F. , Alrabaa, Rami George , Benjamin, C. , Oeding, Jacob F , Wong, Stephanie E. , Zhang, Alan L. , Feeley, Brian T. , Lansdown, Drew Anderson

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | July 16, 2022 | Volume: 31 | Issue: 2 | Pages: 455-463

10.1007/s00167-022-07061-9 | PMID 35841396 Get It

AbstractPurposeThere is little information on patients most at risk for poor outcomes following surgical repair of extensor mechanism tendon injuries. The purpose of this study is to provide an epidemiological overview of patients undergoing patellar or quadriceps tendon repair and to assess the incidence of postoperative complications, readmissions, and revision repairs among this population.MethodsRetrospective data were obtained using the PearlDiver database for patellar tendon repair and quadriceps tendon repair patients between 2010 and 2020. Baseline demographics, incidences of 90‐day readmissions and postoperative complications, and reoperation rates were collected for each group. Multivariate logistic regression was performed to assess the predictive power of each demographic variable on the incidence of postoperative complications and reoperations.ResultsIn total, 1543 patients underwent patellar tendon repair and 601 underwent quadriceps tendon repair. Complications within 90‐days were observed in 33.7% of patients with patellar tendon repair and 39.2% of patients with quadriceps tendon repair. Reoperation rates were 4.2% and 4.8% for patellar tendon repair and quadriceps tendon repair, respectively. Females in both patellar tendon repair and quadriceps tendon repair groups were at significantly higher risk for post‐operative complications (patellar tendon repair OR 3.0, 95% CI 2.4–3.7; quadriceps tendon repair OR 2.9, 95% CI 1.9–4.6; p < 0.001 for both). Older age (p < 0.001), female gender (p < 0.001), CCI (p < 0.001), tobacco use (p < 0.001), and obesity (p < 0.01) were all predictors of experiencing at least one complication following patellar tendon repair. For quadriceps tendon repair, female gender (p < 0.001) and CCI (p < 0.001) were the strongest predictors of experiencing at least one complication, while older age, tobacco use, and obesity (p < 0.05 for all) were also significant independent predictors.ConclusionPatellar tendon repair patients are younger on average than quadriceps tendon repair patients. Although females are less likely to sustain extensor mechanism ruptures compared to males, females are significantly more likely to have at least one complication after quadriceps or patellar tendon repair. These findings may be used by surgeons, patients, and payors to understand who is most at risk for adverse outcomes following extensor mechanism repair surgery, resulting in earlier intervention and counseling to reduce the likelihood of a poor outcome following extensor mechanism repair surgery.Level of evidenceLevel III.
Hepatology Highlights
Tomlinson, Jennifer L. , Watkins, Ryan , Ilyas, Sumera I. , Ilyas, Sumera Irie , Tomlinson, Jennifer , Penrice, Daniel D. , Ayares, Gustavo , Arab, Juan Pablo

Mayo Clinic

Hepatology | July 16, 2022 | Volume: 76 | Issue: 2 | Pages: 287-288

10.1002/hep.32593 Get It

Effect of adaptive servo ventilation on central sleep apnea and sleep structure in systolic heart failure patients: polysomnography data from the SERVE‐HF major sub study
Tamisier, Renaud , Cowie, Martín , Vettorazzi, Eik , Suling, Anna , Angermann, Christiane E. , d’Ortho, Marie‐Pia , Erdmann, Erland , Simonds, Anita K., Teschler, Helmut, Lévy, Patrick , Woehrle, Holger , Lévy, Patrick , Cowie, Martin R , Pépin, Jean‐Louis , Wegscheider, Karl , Somers, Virend K.

Mayo Clinic

Journal of Sleep Research | July 16, 2022 | Volume: 31 | Issue: 6 | Pages: No page available

10.1111/jsr.13694 | PMID 35840352 Get It

SummaryThis SERVE‐HF (Treatment of Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients With Heart Failure) sub study analysis evaluated polysomnography (PSG) data in patients with heart failure with reduced ejection fraction (HFrEF) and predominant central sleep apnea (CSA) randomised to guideline‐based medical therapy, with or without adaptive servo ventilation (ASV). Patients underwent full overnight PSG at baseline and at 12 months. All PSG recordings were analysed by a core laboratory. Only data for patients with baseline and 3‐ or 12‐month values were included. The sub study included 312 patients; the number with available PSG data differed for each variable (94–103 in the control group, 77–99 in the ASV group). After 12 months, baseline‐adjusted respiratory measures were significantly better in the ASV group versus control. Although some between‐group differences in sleep measures were seen at 12 months (e.g., better sleep efficiency in the ASV group), these were unlikely to be clinically significant. The number of periodic leg movements during sleep (PLMS) increased in the ASV group (p = 0.039). At 12 months, the respiratory arousal index was significantly lower in the ASV versus control group (p < 0.001), whilst the PLMS‐related arousal index was significantly higher in the ASV group (p = 0.04 versus control). ASV attenuated the respiratory variables characterising sleep apnea in patients with HFrEF and predominant CSA in SERVE‐HF. Sleep quality improvements during ASV therapy were small and unlikely to be clinically significant. The increase in PLMS and PLMS‐related arousals during ASV warrants further investigation, particularly relating to their potential association with increased cardiovascular risk.
The Development and Initial Validation of the PROMIS®+HF-27 and PROMIS+HF-10 Profiles
Ahmad, Faraz S. , Jackson, Kathryn , Yount, Susan , Rothrock, Nan , Kallen, Michael A. , Lacson, Leilani, Bilimoria, Karl Y. , Mutharasan, R. Kannan , Bruckel, Jeffrey , Fedson, Savitri , Cella, David , Eton, David T. , Ahmad, Faraz , Kho, Abel , McCullough, Peter Andrew , Kimmel, Stephen E. , Grady, Kathleen L , Yancy, Clyde W.

Mayo Clinic

ESC Heart Failure | July 15, 2022 | Volume: 9 | Issue: 5 | Pages: 3380-3392

10.1002/ehf2.14061 | PMID 35841128 Get It

Abstract Aims Heart failure (HF) is a common and morbid condition impacting multiple health domains. We previously reported the development of the PROMIS®-Plus-HF (PROMIS+HF) profile measure, including universal and HF-specific items. To facilitate use, we developed shorter, PROMIS+HF profiles intended for research and clinical use. Methods and results Candidate items were selected based on psychometric properties and symptom range coverage. HF clinicians (n = 43) rated item importance and clinical actionability. Based on these results, we developed the PROMIS+HF-27 and PROMIS+HF-10 profiles with summary scores (0–100) for overall, physical, mental, and social health. In a cross-sectional sample (n = 600), we measured internal consistency reliability (Cronbach's alpha and Spearman–Brown), test–retest reliability (intraclass coefficient; n = 100), known-groups validity via New York Heart Association (NYHA) class, and convergent validity with Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. In a longitudinal sample (n = 75), we evaluated responsiveness of baseline/follow-up scores by calculating mean differences and Cohen's d and comparing with paired t-tests. Internal consistency was good to excellent (α 0.82–0.94) for all PROMIS+HF-27 scores and acceptable to good (α/Spearman–Brown 0.60–0.85) for PROMIS+HF-10 scores. Test–retest intraclass coefficients were acceptable to excellent (0.75–0.97). Both profiles demonstrated known-groups validity for the overall and physical health summary scores based on NYHA class, and convergent validity for nearly all scores compared with KCCQ scores. In the longitudinal sample, we demonstrated responsiveness for PROMIS+HF-27 and PROMIS+HF-10 overall and physical summary scores. For the PROMIS+HF overall summary scores, a group-based increase of 7.6–8.3 points represented a small to medium change (Cohen's d = 0.40–0.42). For the PROMIS+HF physical summary scores, a group-based increase of 5.0–5.9 points represented a small to medium change (Cohen's d = 0.29–0.35). Conclusions The PROMIS+HF-27 and PROMIS+HF-10 profiles demonstrated good psychometric characteristics with evidence of responsiveness for overall and physical health. These new measures can facilitate patient-centred research and clinical care, such as improving care quality through symptom monitoring, facilitating shared decision-making, evaluating quality of care, assessing new interventions, and monitoring during the initiation and titration of guideline-directed medical therapy.
The Effect of Gender-Affirming Surgery on Mental Health in the Transgender Community
Cátala-Rivera, Natalia A., Obando, Duneska D., Piplani, Charoo , Garcia, John P., Torres-Guzman, Ricardo A, Cátala-Rivera, Natalia A, Ramírez, Andrea, Torres‐Guzman, Ricardo A. , Garcia, John P.

Mayo Clinic

Plastic & Reconstructive Surgery | July 15, 2022 | Volume: 150 | Issue: 3 | Pages: 715e-717e

10.1097/prs.0000000000009421 | PMID 35839477 Get It

Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice
Amador, Catalina , Wright, George W. , Weisenburger, Dennis D. , Greiner, Timothy C. , Lone, Waseem , Heavican, Tayla B., Smith, Lynette M. , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Rosenwald, Andreas , Slack, Graham W. , Kim, Won Seog , Hyeh, Young, Li, Yuping , Dong, Gehong, Ondrejka, Sarah L. , Cook, James R. , Lim, Soon Thye , Ong, Choon Kiat , Chapman, Jennifer R. , Raess, Philipp W. , Blombery, Piers , Morris, Stephan W., Staudt, Louis M. , Chan, Wing C. , Iqbal, Javeed , Greiner, Timothy C , Heavican, Tayla B , Smith, Lynette , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Savage, Kerry J , Kim, Won Seog , Hyeh, Young , Song, Joo Y , Ondrejka, Sarah , Cook, James R , Lim, Soon Thye , Ong, Choon Kiat , Inghirami, Giorgio , Raess, Philipp W , Gould, Clare , Jaffe, Elaine S , Vose, Julie , Chan, Wing C , Iqbal, Javeed , Amador, Catalina , Lone, Waseem G , Wright, George , Bouska, Alyssa , Feldman, Andrew L. , Savage, Kerry J. , Ko, Young Hyeh , Song, Joo Y. , Barrionuevo, Carlos , Inghirami, Giorgio , Bhagavathi, Sharathkumar , Gould, Clare , Jaffe, Elaine S. , Rimsza, Lisa M. , Vose, Julie M.

Mayo Clinic

Journal of Clinical Oncology | July 15, 2022 | Volume: 40 | Issue: 36 | Pages: 4261-4275

10.1200/jco.21.02707 | PMID 35839444 Get It

PURPOSE Peripheral T-cell lymphoma (PTCL) includes heterogeneous clinicopathologic entities with numerous diagnostic and treatment challenges. We previously defined robust transcriptomic signatures that distinguish common PTCL entities and identified two novel biologic and prognostic PTCL-not otherwise specified subtypes (PTCL-TBX21 and PTCL-GATA3). We aimed to consolidate a gene expression–based subclassification using formalin-fixed, paraffin-embedded (FFPE) tissues to improve the accuracy and precision in PTCL diagnosis. MATERIALS AND METHODS We assembled a well-characterized PTCL training cohort (n = 105) with gene expression profiling data to derive a diagnostic signature using fresh-frozen tissue on the HG-U133plus2.0 platform (Affymetrix, Inc, Santa Clara, CA) subsequently validated using matched FFPE tissues in a digital gene expression profiling platform (nCounter, NanoString Technologies, Inc, Seattle, WA). Statistical filtering approaches were applied to refine the transcriptomic signatures and then validated in another PTCL cohort (n = 140) with rigorous pathology review and ancillary assays. RESULTS In the training cohort, the refined transcriptomic classifier in FFPE tissues showed high sensitivity (> 80%), specificity (> 95%), and accuracy (> 94%) for PTCL subclassification compared with the fresh-frozen–derived diagnostic model and showed high reproducibility between three independent laboratories. In the validation cohort, the transcriptional classifier matched the pathology diagnosis rendered by three expert hematopathologists in 85% (n = 119) of the cases, showed borderline association with the molecular signatures in 6% (n = 8), and disagreed in 8% (n = 11). The classifier improved the pathology diagnosis in two cases, validated by clinical findings. Of the 11 cases with disagreements, four had a molecular classification that may provide an improvement over pathology diagnosis on the basis of overall transcriptomic and morphological features. The molecular subclassification provided a comprehensive molecular characterization of PTCL subtypes, including viral etiologic factors and translocation partners. CONCLUSION We developed a novel transcriptomic approach for PTCL subclassification that facilitates translation into clinical practice with higher precision and uniformity than conventional pathology diagnosis.
Characterization of Platelet Biologic Markers in the Early Pathogenesis of Postoperative Acute Respiratory Distress Syndrome
Yadav, Hemang , Meade, Laurie, Carter, Rickey E. , Knutson, Keith L. , Kor, Daryl J. , Meade, Laurie A., Knutson, Keith, Carter, Rickey E , Knutson, Keith L. , Gajic, Ognjen

Mayo Clinic

Critical Care Explorations | July 15, 2022 | Volume: 4 | Issue: 7 | Pages: e0728

10.1097/cce.0000000000000728 | PMID 36818750 Get It

IMPORTANCE: Animal models and limited human studies have suggested a plausible role for platelets in the pathogenesis and resolution of acute respiratory distress syndrome (ARDS). However, there are little data regarding the role of platelets in ARDS development. OBJECTIVES: The objective of this study was to characterize the role of platelets in a postoperative ARDS model through an analysis of two platelet-specific biologic markers: thromboxane A2 (TxA2) and soluble CD-40-ligand (sCD40L). DESIGN, SETTING, AND PARTICIPANTS: This was a nested case-control study of ARDS cases matched to non-ARDS controls. Blood samples were collected from a cohort of 500 patients undergoing thoracic, aortic vascular, or cardiac surgery that placed them at high-risk of developing postoperative ARDS. MAIN OUTCOMES AND MEASURES: TxA2 and sCD40L were analyzed at baseline (prior to surgical incision) as well as 2 hours and 6 hours after the key intraoperative events believed to be associated with increased risk of postoperative ARDS. RESULTS: Of 500 patients enrolled, 20 ARDS cases were matched 1:2 to non-ARDS controls based on age, sex, surgical procedure, and surgical lung injury prediction score. Those who developed ARDS had longer surgeries, greater fluid administration, and higher peak inspiratory pressures. There were no significant differences in levels of TxA2 or sCD40L at baseline, at 2 hours, or at 6 hours. There was also no difference in the change in biomarker concentration between baseline and 2 hours or baseline and 6 hours. CONCLUSIONS: Two novel platelet-associated biologic markers (TxA2 and sCD40L) were not elevated in patients who developed ARDS in a postoperative ARDS model. Although limited by the relatively small study size, these results do not support a clear role for platelets in the early pathogenesis of postoperative ARDS.
Double Stenting for Management of a Bronchoesophageal Fistula
Castillo‐Larios, Rocio , Hernandez‐Rojas, Daniel , Lee‐Mateus, Alejandra Yu , Gómez, Victoria , Koop, Andree , Fernández-Bussy, Sebastián , Yu Lee-Mateus, Alejandra , Abia‐Trujillo, David

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | July 15, 2022 | Volume: 30 | Issue: 1 | Pages: 77-79

10.1097/lbr.0000000000000843 | PMID 35839319 Get It